Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24244Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Fountzilas, G. | en |
| dc.contributor.author | Athanassiades, A. | en |
| dc.contributor.author | Giannakakis, T. | en |
| dc.contributor.author | Briasoulis, E. | en |
| dc.contributor.author | Bafaloukos, D. | en |
| dc.contributor.author | Kalogera-Fountzila, A. | en |
| dc.contributor.author | Onienaoum, A. | en |
| dc.contributor.author | Kalofonos, H. | en |
| dc.contributor.author | Pectasides, D. | en |
| dc.contributor.author | Andreopoulou, E. | en |
| dc.contributor.author | Bamia, C. | en |
| dc.contributor.author | Kosmidis, P. | en |
| dc.contributor.author | Pavlidis, N. | en |
| dc.contributor.author | Skarlos, D. | en |
| dc.date.accessioned | 2015-11-24T19:39:25Z | - |
| dc.date.available | 2015-11-24T19:39:25Z | - |
| dc.identifier.issn | 0923-7534 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24244 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Antibiotics, Antineoplastic/*administration & dosage/adverse effects | en |
| dc.subject | Breast Neoplasms/*drug therapy | en |
| dc.subject | Disease-Free Survival | en |
| dc.subject | Drug Administration Schedule | en |
| dc.subject | Epirubicin/*administration & dosage/adverse effects | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Middle Aged | en |
| dc.subject | Survival Analysis | en |
| dc.subject | Treatment Outcome | en |
| dc.title | A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/9496386 | - |
| heal.identifier.secondary | http://annonc.oxfordjournals.org/content/8/12/1213.full.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1997 | - |
| heal.abstract | PURPOSE: To evaluate the impact on the response rate in patients with advanced breast cancer (ABC) of the doubling of the dose intensity (DI) of epirubicin monotherapy. PATIENTS AND METHODS: From January 1991 until April 1996, 167 patients with ABC were randomized to receive epirubicin (110 mg/m2) either every four (81 patients, group A) or every two weeks (86 patients, group B). Filgrastim (5 micrograms/kg/daily) was administered prophylactically on days 2-12 of each cycle. RESULTS: The two groups were equally balanced in terms of major patient and tumor characteristics. Even though the median cumulative dose of epirubicin was identical in the two groups (651 mg/m2), the median DI of epirubicin was doubled in group B (27.2 vs. 52.9 mg/m2/wk, respectively). The complete response (CR) rate was significantly increased in group B (5%, 95% CI: 0.16%-9.84% vs. 17%, 95% CI: 8.9%-25.08%, P = 0.011), although overall response rates were similar (49% vs. 53%, P = 0.5957). Also, there was no significant difference in the incidence of grade 3-4 toxicity between the two groups. After a median follow-up of 25 months (range, 0.43-43.3+) no significant difference was observed in the duration of response (median, 10 months vs. 8.5 months, P = 0.5130), time to progression (median, 7.2 months vs. 7.4 months, P = 0.2970) or survival (median, 14.6 months vs. 14.9 months, P = 0.4483). Logistic regression analysis showed that performance status was a significant variable for response (P = 0.0068) and multivariate analysis using the Cox proportional hazards model revealed that performance status was significant for survival (P = 0.0049), while the presence of multiple metastases (P = 0.0020) was significant for time to progression. CONCLUSION: Doubling the planned DI of epirubicin monotherapy significantly increases the CR rate but has no influence on time to progression or survival in patients with ABC. | en |
| heal.journalName | Ann Oncol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Fountzilas-1997-A randomized study o.pdf | 1.71 MB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
